Finorify

LLY

Eli Lilly & Co

$1,151-1.64%

Price

LLY daily closing price
Market cap
$1.03 trillion
P/E (TTM)
38.62
EV/EBITDA
18.93
52W range
$714.59 – $1,280
Div yield
0.56%
Volume
2.1M
Sector
Healthcare

Eli Lilly & Co (LLY) last closed at $1,151, on a daily price path from October 21, 2025 to October 21, 2026. Overview is that price path. Performance is the change in the close over the periods Finorify shows on the stock screen. Financials, cash flow, and margins come from reported quarters. Valuation lists the latest ratios. This snapshot is the Finorify stock screen for LLY, covered for search and blurred for visitors.

Performance

  • 1D-1.01%
  • 5D+5.13%
  • 1M+8.60%
  • 3M+7.16%
  • 6M+37.90%
  • 1Y+57.08%
  • 5Y+437.45%

Financials

LLY revenueQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Over the latest four reported periods ending June 30, 2026, Eli Lilly & Co reported revenue of $79.67 billion.

The prior window totaled $53.26 billion, so the latest window is higher than that stretch.

Operating cash flow in the latest window was $28.08 billion.

Free cash flow in the latest window was $18.19 billion.

These amounts are taken from Eli Lilly & Co's SEC filings and are a snapshot as of June 30, 2026. They are not a live price, and they are not a recommendation to buy or sell. Finorify uses the same filings to draw the charts inside the app.

A few ratios from those statements: Profitability: ROE 20.9% (86 of 100). Leverage: D/E 1.41× (43 of 100). Cash generation: FCF margin 22.8% (46 of 100). Net margin: 30.9% (77 of 100). Liquidity: Current 1.35× (68 of 100).

Finorify's notes from those filings, written August 27, 2026: Robust Proprietary R&D and Leading Incretin Franchise. Eli Lilly possesses industry-leading research and development capabilities, driving breakthroughs in high-demand therapeutic categories such as metabolic diseases (e.g., tirzepatide for type 2 diabetes and obesity), oncology, immunology, and neuroscience. Its extensive patent portfolio and clinical pipeline create high technological barriers to entry and long product exclusivity periods. Specialized Biologic and Device Manufacturing Scale. The company has invested billions into high-complexity sterile manufacturing, peptide synthesis, and automated drug-device combination assembly (such as auto-injector pens). This specialized, capital-intensive manufacturing network is difficult for competitors to replicate and provides significant economies of scale and quality advantages. Expansive Global Commercialization and Payer Access Network. Lilly maintains a vast global commercial infrastructure and established relationships with healthcare providers, pharmacy benefit managers, and national health authorities. This allows the company to secure favorable formulary positioning, negotiate reimbursement, and rapidly scale newly launched blockbuster therapies worldwide. Patent Expirations and Biosimilar/Generic Erosion. The pharmaceutical business model depends on patent exclusivity. As key revenue-generating drugs lose patent protection, Lilly faces immediate revenue declines and margin compression from lower-cost generic small molecules and biosimilar alternatives. Regulatory Pricing Controls and Payer Reimbursement Pressures. Lilly is heavily exposed to drug pricing legislation (such as Medicare drug price negotiations under the U.S. Inflation Reduction Act) and aggressive rebating demands from pharmacy benefit managers and single-payer healthcare systems, which can constrain net pricing realization. Clinical Trial Failures and Strict Regulatory Oversight. Developing novel pharmaceuticals involves substantial capital risk, long development timelines, and high failure rates in clinical trials. Even after approval, unexpected adverse safety signals or manufacturing compliance issues can result in label restrictions, regulatory penalties, or product recalls.

Cash Flow

LLY free cash flowQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Margins

LLY operating margin

Valuation

P/E (TTM)
38.62
P/S (TTM)
12.89
EV/EBITDA
18.93

Insights

Advantage

Robust Proprietary R&D and Leading Incretin Franchise

Eli Lilly possesses industry-leading research and development capabilities, driving breakthroughs in high-demand therapeutic categories such as metabolic diseases (e.g., tirzepatide for type 2 diabetes and obesity), oncology, immunology, and neuroscience. Its extensive patent portfolio and clinical pipeline create high technological barriers to entry and long product exclusivity periods.

Advantage

Specialized Biologic and Device Manufacturing Scale

The company has invested billions into high-complexity sterile manufacturing, peptide synthesis, and automated drug-device combination assembly (such as auto-injector pens). This specialized, capital-intensive manufacturing network is difficult for competitors to replicate and provides significant economies of scale and quality advantages.

Advantage

Expansive Global Commercialization and Payer Access Network

Lilly maintains a vast global commercial infrastructure and established relationships with healthcare providers, pharmacy benefit managers, and national health authorities. This allows the company to secure favorable formulary positioning, negotiate reimbursement, and rapidly scale newly launched blockbuster therapies worldwide.

Risk

Patent Expirations and Biosimilar/Generic Erosion

The pharmaceutical business model depends on patent exclusivity. As key revenue-generating drugs lose patent protection, Lilly faces immediate revenue declines and margin compression from lower-cost generic small molecules and biosimilar alternatives.

Risk

Regulatory Pricing Controls and Payer Reimbursement Pressures

Lilly is heavily exposed to drug pricing legislation (such as Medicare drug price negotiations under the U.S. Inflation Reduction Act) and aggressive rebating demands from pharmacy benefit managers and single-payer healthcare systems, which can constrain net pricing realization.

Risk

Clinical Trial Failures and Strict Regulatory Oversight

Developing novel pharmaceuticals involves substantial capital risk, long development timelines, and high failure rates in clinical trials. Even after approval, unexpected adverse safety signals or manufacturing compliance issues can result in label restrictions, regulatory penalties, or product recalls.

Read the live analysis in Finorify

Charts, news, and the written notes are in the app. You can open five distinct stocks free. After that, the stock screen is a Finorify Pro feature.

Open LLY in Finorify